Evidence map›Paper›PMID 39468772›Full record

ArticleEuropean journal of clinical investigation2025

Comparative assessment of phenotypic markers in patients with chronic inflammation: Differences on Bifidobacterium concerning liver status.

Lourdes Chero-Sandoval, Andrea Higuera-Gómez, María Martínez-Urbistondo, Raquel Castejón, Susana Mellor-Pita, Víctor Moreno-Torres, Daniel de Luis, Amanda Cuevas-Sierra, J Alfredo Martínez

Abstract readComparative Study
In one paragraph

Article in European journal of clinical investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lourdes Chero-SandovalPrecision Nutrition and Cardiometabolic Health, IMDEA-Food Institute (Madrid Institute for Advanced Studies), Campus of International Excellence (CEI) UAM+CSIC, Madrid, Spain.
Andrea Higuera-GómezPrecision Nutrition and Cardiometabolic Health, IMDEA-Food Institute (Madrid Institute for Advanced Studies), Campus of International Excellence (CEI) UAM+CSIC, Madrid, Spain.
María Martínez-UrbistondoInternal Medicine Service, Puerta de Hierro Majadahonda University Hospital, Madrid, Spain.
Raquel CastejónInternal Medicine Service, Puerta de Hierro Majadahonda University Hospital, Madrid, Spain.
Susana Mellor-PitaInternal Medicine Service, Puerta de Hierro Majadahonda University Hospital, Madrid, Spain.
Víctor Moreno-TorresInternal Medicine Service, Puerta de Hierro Majadahonda University Hospital, Madrid, Spain.ORCID https://orcid.org/0000-0002-9798-4514
Daniel de LuisDepartment of Endocrinology and Nutrition, University Clinical Hospital, University of Valladolid, Valladolid, Spain.
Amanda Cuevas-SierraPrecision Nutrition and Cardiometabolic Health, IMDEA-Food Institute (Madrid Institute for Advanced Studies), Campus of International Excellence (CEI) UAM+CSIC, Madrid, Spain.ORCID https://orcid.org/0000-0003-2631-2566
J Alfredo MartínezPrecision Nutrition and Cardiometabolic Health, IMDEA-Food Institute (Madrid Institute for Advanced Studies), Campus of International Excellence (CEI) UAM+CSIC, Madrid, Spain.

Funding

Opiate Withdrawal &Tolerance: Development &PlasticityR01DA006600 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI BARR, GORDON ALFRED · 1989 to 2006
$1.4M
Consejería de Educación, Juventud y Deporte, Comunidad de Madrid Y2020/6600Instituto de Salud Carlos III CD22/00011
6 · The paper itself

Abstract

backgroundThe relationship between systemic lupus erythematosus (SLE) and low-grade metabolic inflammation (MI) with the microbiota is crucial for understanding the pathogenesis of these diseases and developing effective therapeutic interventions. In this context, it has been observed that the gut microbiota plays a key role in the immune regulation and inflammation contributing to the exacerbation through inflammatory mediators. This research aimed to describe similarities/differences in anthropometric, biochemical, inflammatory, and hepatic markers as well as to examine the putative role of gut microbiota concerning two inflammatory conditions: SLE and MI.

methodsData were obtained from a cohort comprising adults with SLE and MI. Faecal samples were determined by 16S technique. Statistical analyses compared anthropometric and clinical variables, and LEfSe and MetagenomeSeq were used for metagenomic data. An interaction analysis was fitted to investigate associations of microbiota with fatty liver index (FLI) depending on the inflammatory condition.

resultsParticipants with low-grade MI showed worse values in anthropometry and biochemicals compared with patients with SLE. The liver profile of patients with MI was unhealthier, while no relevant differences were found in most of the inflammatory markers between groups. LEfSe analysis revealed an overrepresentation of Bifidobacteriaceae family in SLE group. An interactive association between gut Bifidobacterium abundance and type of disease was identified for FLI values, suggesting an effect modification of the gut microbiota concerning liver markers depending on the inflammatory condition.

conclusionThis study found phenotypical and microbial similarities and disparities between these two inflammatory conditions, evidenced in clinical and hepatic markers, and showed the interactive interplay between gut Bifidobacterium and liver health (measured by FLI) that occur in a different manner depending on the type of inflammatory disease. These results underscore the importance of personalized approaches and individual microbiota in the screening of different inflammatory situations, considering unique hepatic and microbiota profiles.

Indexed as

BifidobacteriumFatty LiverGastrointestinal MicrobiomeInflammationLupus Erythematosus, SystemicAdultBiomarkersChronic DiseaseFecesFemaleHumansMaleMiddle AgedPhenotypeBiomarkersBifidobacteriumFatty Liver Indexgut microbiotahepatic statussystemic lupus erythematosus

Identifiers

PMID39468772
PMCPMC11744921

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.